Paul Hopkins, MD Talks Correlation Between Weight Gain and Familial Dysbetalipoproteinemia
Paul Hopkins, MD
At the 2017 National Lipid Association Sessions in Philadelphia, Rare Disease Report sat down with Paul Hopkins, MD to talk about the relation between familial dysbetalipoproteinemia (aka type 3 hyperlipoproteinemina) and weight gain in patients diagnosed with it.
RDR: Are there any key influencers of familial dysbetalipoproteinemia?
Hopkins: It's highly influenced by bodyweight, so if you gain weight, or if you're overweight, there's a much bigger likelihood that it will be manifest. So, losing weight is one of the priorities. Most saturated fat – things like that can help some, but weight loss trumps all, and lower sugar diets help. Then, we turn to fibrates, typically, as the first drug and often statins. Sometimes, people respond so well to a statin the clinician has no idea that they're treating type 3 hyperlipoproteinemia. But it responds pretty well, so they're happy, so it never gets really diagnosed.
RDR: Why does the diagnosis of familial dysbetalipoproteinemia correlate with weight gain?
Hopkins: It's increased production of the LDL particles, so the triglyceride bearing particles that the liver makes; the rate that those are being made is largely determined by how much is fat is coming from the fat tissues into the liver and then sent out again and the heavier you are, on average, the more of those particles you produce.